FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
A new FDA‑approved drug gives ADHD patients of all ages a first‑in‑class treatment option.
📍 The outcome
The FDA approved Otsuka’s first‑in‑class ADHD medication, Simtriyo (centanafidine), for patients six years and older, covering children, adolescents and adults. This approval was highlighted as the first new‑class ADHD drug in decades and concluded the recent coverage of the medication’s regulatory review.
Epilogue added 43d ago, after coverage quieted.
Who reported it (5)
- Centanafadine's Route to FDA Review: A Clinical Path of the ADHD Medication Psychiatric Times · 47d ago
- Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older mykxlg.com · 47d ago
- FDA Rules Today on First New-Class ADHD Drug for Kids and Adults in Decades Medical Daily · 47d ago
- Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD FirstWord Pharma · 47d ago
- FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults Psychiatric Times · 47d ago
The brief
Patients and families will now have a newly approved medication option for ADHD across ages. The FDA has granted approval for centanafadine, marketed as SimtriYo®, for children, adolescents and adults.
Otsuka’s triple‑reuptake inhibitor arrives as the first new‑class ADHD drug in decades, following a clinical path outlined by Psychiatric Times. The decision opens questions about how clinicians will integrate the drug into existing treatment regimens.
Otsuka’s receipt of the clearance, reported by mykxlg.com, confirms the product meets regulatory standards. Ongoing monitoring will determine the medication’s safety profile and real‑world effectiveness.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (86% supported) Updated 43d ago.
Quick answers
Which age groups are covered by the FDA approval?
The approval includes children, adolescents and adults, specifically patients aged 6 years and older.
Under what brand name is centanafadine marketed?
The medication is marketed as SimtriYo®.
What class of drug is centanafadine described as?
It is described as a first‑in‑class triple‑reuptake inhibitor, a new class of ADHD treatment.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
CEOs Pushed White House to Delay Ultra-Processed Food Policy
Corporate lobbying and White House maneuvering have collided over the FDA's controversial new ultra-processed food definition.
FDA Announces Recall on Berries Sold in 8 States for Potential E. Coli Contamination
The FDA and Publix have issued a recall for frozen berries across eight states following an E. coli outbreak linked to the products.
More cases reported in cyclospora outbreak not linked to lettuce: FDA data
Cyclospora infections are rising across the U.S., with recent data indicating new outbreak clusters that fall outside the traditional link to lettuce products.
Can you eat lettuce safely during the cyclospora outbreak? Advice from an infectious disease expert
Cyclospora outbreaks are fueling regional health concerns and economic strain in the restaurant industry as officials navigate complex data and public messaging.
Toward a test of medical AI superintelligence
A new medical AI framework sparks debate over FDA benchmarks and the path to superintelligence.
Cyclospora and salmonella outbreaks raise concerns about U.S. food safety
Rising cyclosporiasis cases push 11,000 infections into the spotlight as the U.S. food safety system faces fresh scrutiny